^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

Published date:
05/04/2023
Excerpt:
We investigated a gene panel to prognosticate abemaciclib susceptibility in patients with ESR1-MUT MBC after palbociclib progression….For ESR1-MUT MBC with resistance to ET and palbociclib, PFS on abemaciclib is longer for patients with CDKi-R(–) than CDKi-R(+).
DOI:
10.1200/PO.22.00532
Evidence Level:
Sensitive: C4 – Case Studies
Title:

[ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib]

Published date:
08/23/2023
Excerpt:
Here, we describe our experience of a case in which long-term PR was achieved with AI(letrozole)plus abemaciclib despite ESR1 mutation positivity in cancer genetic screening and review the literature.
Secondary therapy:
letrozole